Hemogenyx Pharmaceuticals PLC
LSE:HEMO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
130
1 545
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
48.4m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
393.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Hemogenyx Pharmaceuticals PLC
Glance View
HemoGenyx Pharmaceuticals Plc operates as a biopharmaceutical company, which engages in the development of novel therapies to transform bone marrow and blood stem cell transplantation. The firm is engaged in the discovery, development, and commercialization of a suite of products to address the problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, with viral infections, and with bone marrow, or hematopoietic stem cell, transplants. The Company’s product candidates include CDX antibody, CAR-T cell therapy, Hu-PHEC stem cell therapy, Humanised mice, and CBR platform. Its CDX antibody product, is a bispecific antibody targeting a form of relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia (ALL), and myelodysplastic syndrome. CAR-T cell therapy is a chimeric antigen receptor T-cells that are engineered for use in immunotherapy. The Company’s human postnatal hemogenic endothelial cells (Hu-PHECs) are a type of cell therapy that generate cancer-free hematopoietic stem cells for use in transplants to treat blood disorders.